Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the American College of Cardiology

• Publication date

  1999-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0735-1097(99)00025-XPMID 10193712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events.

  1999cited by this paper
• Valsartan in heart failure patients previously untreated with an ACE inhibitor.

  1998cited by this paper
• The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats.

  1998cited by this paper
• AT2 receptor blockade reduces cardiac interstitial cell DNA synthesis and cardiac function after rat myocardial infarction.

  1998cited by this paper
• Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.

  1998cited by this paper
• Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction.

  1998cited by this paper
• Irbesartan Compared With Lisinopril in Patients With Mild to Moderate Heart Failure

  1998cited by this paper
• Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.

  1998cited by this paper
• Alternative pathways of angiotensin II production in the human saphenous vein

  1998cited by this paper
• Functional effects of endogenous bradykinin in congestive heart failure.

  1998cited by this paper
• Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure.

  1998cited by this paper
• Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators.

  1998cited by this paper
• Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.

  1998cited by this paper
• Plasma bradykinin in angio-oedema.

  1998cited by this paper
• Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure.

  1998cited by this paper
• Angiotensin II receptor blockade combined to ace-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure

  1998cited by this paper
• ACE Inhibitor-Induced Angioedema

  1998cited by this paper
• Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts.

  1997cited by this paper
• Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

  1997cited by this paper
• Valsartan, a New Angiotensin II Receptor Antagonist: A Double‐Blind Study Comparing the Incidence of Cough with Lisinopril and Hydrochlorothiazide

  1997cited by this paper
• Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats.

  1997cited by this paper
• Angiotensin II Enhances Baroreflex Control of Sympathetic Outflow in Heart Failure

  1997cited by this paper
• Differential Distribution of Angiotensin AT 2 Receptors in the Normal and Failing Human Heart 1

  1997cited by this paper
• Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.

  1997cited by this paper
• Kinin receptors in human vascular tissue: their role in atheromatous disease.

  1997cited by this paper
• Double‐Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin‐Converting Enzyme Inhibitor‐Induced Cough

  1997cited by this paper
• Mechanisms and implications of autonomic nervous system dysfunction in heart failure.

  1997influential reference
• Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.

  1997cited by this paper
• Evidence-Based, Cost-effective Risk Stratification and Management After Myocardial Infarction

  1997cited by this paper
• Local application of angiotensin II to the rat carotid artery induces adventitial thickening.

  1997cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997influential reference
• Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.

  1997cited by this paper
• Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation.

  1997cited by this paper
• Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

  1997cited by this paper
• Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin

  1997cited by this paper
• Apoptosis in the failing human heart.

  1997cited by this paper
• Angiotensin II blockade [corrected] enhances baroreflex control of sympathetic outflow in heart failure.

  1997cited by this paper
• Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.

  1997cited by this paper
• Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts.

  1997cited by this paper
• Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts.

  1997cited by this paper
• National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure.

  1997cited by this paper
• Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.

  1997cited by this paper
• Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart.

  1997cited by this paper
• Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme.

  1997cited by this paper
• Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.

  1997cited by this paper
• Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure.

  1997cited by this paper
• Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.

  1997cited by this paper
• Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism.

  1997cited by this paper
• Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure.

  1997cited by this paper
• Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?

  1997cited by this paper
• Underutilization of evidence-based therapy in heart failure. An opportunity to deal a winning hand with ace up your sleeve.

  1997cited by this paper
• Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues.

  1997cited by this paper
• Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening.

  1997cited by this paper
• Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans.

  1997cited by this paper
• Variations in cholesterol management practices of U.S. physicians.

  1997cited by this paper
• Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management.

  1997cited by this paper
• Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor.

  1997cited by this paper
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  1996cited by this paper
• Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials

  1996cited by this paper
• Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals.

  1996cited by this paper
• Angiotensin II type 2 receptor mediates programmed cell death.

  1996cited by this paper
• Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).

  1996cited by this paper
• The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease.

  1996cited by this paper
• Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.

  1996cited by this paper
• Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure.

  1996cited by this paper
• Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction)

  1996cited by this paper
• Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.

  1996cited by this paper
• Chymase-dependent angiotensin II forming systems in humans.

  1996cited by this paper
• Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure.

  1996cited by this paper
• ACE Inhibitor-Induced Cough and Bronchospasm

  1996cited by this paper
• ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.

  1996cited by this paper
• Angiotensin receptors.

  1996cited by this paper
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  1996cited by this paper
• Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

  1996cited by this paper
• Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts.

  1996cited by this paper
• ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in Prescription-Event Monitoring

  1996cited by this paper
• Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.

  1996cited by this paper
• Increased sensitivity to bradykinin among African Americans.

  1996cited by this paper
• Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.

  1996cited by this paper
• The effect of bradykinin and substance P on the arachidonate cascade of platelets.

  1996cited by this paper
• National patterns of warfarin use in atrial fibrillation.

  1996cited by this paper
• Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation.

  1996cited by this paper
• Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: ROLE OF AT1 RECEPTORS IN THE CENTRAL CONTROL OF SYMPATHETIC VASOMOTOR FUNCTION

  1996cited by this paper
• Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

  1995cited by this paper
• Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial

  1995cited by this paper
• Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

  1995cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy

  1995cited by this paper
• Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P.

  1995cited by this paper
• Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors

  1995cited by this paper
• Renal function in one‐kidney, one clip sodium‐restricted rats: influence of enalapril and losartan

  1995cited by this paper
• Adverse consequences of high sympathetic nervous activity in the failing human heart.

  1995cited by this paper
• Role of the fibrinolytic system in preventing myocardial infarction.

  1995cited by this paper
• Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)

  1995cited by this paper
• Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.

  1995cited by this paper
• Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Improving survival for patients with advanced heart failure: a study of 737 consecutive patients.

  1995cited by this paper
• Fibrinogen in ischaemic heart disease.

  1995cited by this paper
• Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.

  1995cited by this paper

• A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children

  2024cites this paper
• Reinventing the renin–angiotensin–aldosterone system based on experience from the COVID‐19 pandemic

  2024cites this paper
• Long‐term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real‐world database: A retrospective cohort study

  2023cites this paper
• Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future

  2022cites this paper
• From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19

  2020cites this paper
• Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins

  2019cites this paper
• Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report

  2017cites this paper
• Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure

  2016cites this paper
• Purification and identification of angiotensin I-converting enzyme-inhibitory peptides from apalbumin 2 during simulated gastrointestinal digestion.

  2015cites this paper
• Cardiovascular Research: Past, Present and Future

  2015cites this paper
• Experimental Vein Graft Research: A Critical Appraisal of Models

  2015cites this paper
• Comparison of High and Low Doses of Captopril in the Treatment of Neonates with Left-to-Right Shunt

  2014cites this paper
• Noninvasive imaging of myocardial extracellular matrix for assessment of fibrosis

  2013cites this paper
• angiotensin converting enzyme inhibitors in patients with chronic heart failure Persistent formation of angiotensin II despite treatment with maximally recommended doses of

  2013cites this paper
• Response of cardiac sympathetic nerve activity to intravenous irbesartan in heart failure.

  2010cites this paper
• Heart failure treatment in the intensive care unit in children.

  2010cites this paper
• Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction

  2008cites this paper
• Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique.

  2007cites this paper
• Effekte des Antagonismus von Endothelin- und Angiotensin- Rezeptoren auf Kardiomyozyten bei experimenteller Herzinsuffizienz

  2007cites this paper
• Early imaging in heart failure: Exploring novel molecular targets

  2007cites this paper
• Novel imaging strategies for predicting remodeling and evolution of heart failure: targeting the Renin-Angiotensin system.

  2006influential citation
• Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.

  2006cites this paper
• Imaging the renin-angiotensin-aldosterone system in the heart

  2005cites this paper
• An Echocardiographic Analysis of the Long‐Term Effects of Carvedilol on Left Ventricular Remodeling, Systolic Performance, and Ventricular Filling Patterns in Dilated Cardiomyopathy

  2005cites this paper
• Angiotensin Receptor Blockers in Congestive Heart Failure: Evidence, Concerns, and Controversies

  2005cites this paper
• Angiotensin II attenuates NMDA receptor-mediated neuronal cell death and prevents the associated reduction in Bcl-2 expression.

  2004cites this paper
• Sympathetic interactions of AT1 receptors

  2004cites this paper
• International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children.

  2004cites this paper
• Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.

  2004cites this paper
• The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure

  2004cites this paper
• Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system.

  2003cites this paper
• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.

  2003influential citation
• Angiotensin II Receptor Blockers in Heart Failure

  2003cites this paper
• Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial.

  2003cites this paper
• Impact of chymase inhibitor on cardiac function and survival after myocardial infarction.

  2003cites this paper
• The acute effects of cilazapril on pulmonary function tests and arterial blood gas changes in patients with pulmonary hypertension.

  2003cites this paper
• Medical and surgical treatment of chronic heart failure.

  2003cites this paper
• Pre- and postsynaptic studies concerning the interaction between the renin angiotensin system and the sympathetic nervous system

  2003cites this paper
• The role of angiotensin II receptor blockers in the treatment of heart failure patients.

  2003cites this paper
• Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.

  2002cites this paper
• Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials.

  2002cites this paper
• Angiotensin II receptor antagonists and sympathetic neurotransmission

  2002cites this paper
• [Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure].

  2002cites this paper
• Adición de un ARAII al tratamiento con dosis máximas de IECA en la insuficiencia cardíaca

  2002cites this paper
• Addition of an Angiotensin II Receptor Blocker to Maximal Dose of ACE Inhibitors in Heart Failure

  2002cites this paper
• Dose‐Dependent Blockade of the Angiotensin II Type 1 Receptor with Losartan in Normal Volunteers

  2001cites this paper
• Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.

  2001cites this paper
• Nuevos farmacos en insuficiencia cardíaca

  2001cites this paper
• [New pharmacological agents in heart failure].

  2001cites this paper
• New Competition in the Realm of Renin—Angiotensin Axis Inhibition; the Angiotensin II Receptor Antagonists in Congestive Heart Failure

  2001cites this paper
• Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.

  2001cites this paper
• An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.

  2001cites this paper
• Angiotensin receptor blockers for heart failure.

  2001cites this paper
• [Value of training-induced effects on arterial vascular system and skeletal muscles in therapy of NYHA II/III heart failure].

  2001cites this paper
• Combined angiotensin converting enzyme inhibition and angiotensin AT 1 receptor blockade up-regulates myocardial AT receptors in remodeled

  2001cites this paper
• B 2 kinin receptors: a major player in the release of nitric oxide and EDHF

  2001cites this paper
• O comportamento do sistema renina-angiotensina na insuficiência cardíaca congestiva

  2001cites this paper
• Herzinsuffizienz: AT1-Rezeptor-Blocker als Ergänzung zur optimalen Standardtherapie?

  2001cites this paper
• Stellenwert von trainingsbedingten Rückwirkungen am arteriellen Gefäßsystem und der Skelettmuskulatur in der Therapie der Herzinsuffizienz NYHA II/III

  2001cites this paper
• Basics of Heart Failure

  2000cites this paper
• Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure

  2000influential citation
• Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

  2000cites this paper
• Fifteen years of ACE-inhibition in congestive heart failure.

  2000cites this paper
• New drugs in the treatment of heart failure.

  2000cites this paper
• Drugs in Development: New Agents, New Classes, New Indications

  2000cites this paper
• Effect of losartan on angiotensin II-mediated endothelin and prostanoid excretion in humans.

  2000cites this paper
• The role of angiotensin receptor blockers in heart failure.

  2000cites this paper
• Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

  2000cites this paper
• Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors

  2000cites this paper